Search hospitals > Pennsylvania > Harrisburg

UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Claim this profile
Harrisburg, Pennsylvania 17109
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
90 reported clinical trials
21 medical researchers
Photo of UPMC Pinnacle Cancer Center/Community Osteopathic Campus in HarrisburgPhoto of UPMC Pinnacle Cancer Center/Community Osteopathic Campus in HarrisburgPhoto of UPMC Pinnacle Cancer Center/Community Osteopathic Campus in Harrisburg

Summary

UPMC Pinnacle Cancer Center/Community Osteopathic Campus is a medical facility located in Harrisburg, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. UPMC Pinnacle Cancer Center/Community Osteopathic Campus is involved with conducting 90 clinical trials across 135 conditions. There are 21 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Dan P. Zandberg, and Anuradha Krishnamurthy.

Area of expertise

1Cancer
Global Leader
UPMC Pinnacle Cancer Center/Community Osteopathic Campus has run 44 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
UPMC Pinnacle Cancer Center/Community Osteopathic Campus has run 27 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Breast Cancer
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Squamous Cell Carcinoma
Colorectal Cancer
Oropharyngeal Carcinoma
Small Cell Lung Cancer
Oral Squamous Cell Carcinoma
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Sacituzumab Govitecan

for Brain Metastases from Breast Cancer

This study is evaluating whether a combination of a chemotherapy drug and a monoclonal antibody may help treat breast cancer that has spread to the brain.
Recruiting1 award Phase 212 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at UPMC Pinnacle Cancer Center/Community Osteopathic Campus?
UPMC Pinnacle Cancer Center/Community Osteopathic Campus is a medical facility located in Harrisburg, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. UPMC Pinnacle Cancer Center/Community Osteopathic Campus is involved with conducting 90 clinical trials across 135 conditions. There are 21 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Dan P. Zandberg, and Anuradha Krishnamurthy.